Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood samples in young patients with cytopenia after undergoing a donor stem cell transplant.
| Condition | Intervention |
|---|---|
|
Leukemia Myelodysplastic Syndromes |
Genetic: polymerase chain reaction Other: flow cytometry Other: laboratory biomarker analysis Procedure: allogeneic hematopoietic stem cell transplantation |
| Study Type: | Observational |
| Official Title: | Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) |
- Number of patients with complete chimerism as measured by standard short tandem nucleotide polymorphism PCR in whole blood and the different cell populations [ Designated as safety issue: No ]
- Number of patients with complete chimerism as measured by single nucleotide polymorphisms PCR in the different cell populations [ Designated as safety issue: No ]
- Number of patients with mixed chimerism and full hematological recovery at day 100 [ Designated as safety issue: No ]
- Number of patients with mixed chimerism and acute or chronic graft-versus-host disease [ Designated as safety issue: No ]
| Estimated Enrollment: | 125 |
| Study Start Date: | April 2007 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- To study hematopoietic chimerism in whole blood and different cell populations (i.e., CD14, CD15, CD 56, CD3, and CD19) as well as in dendritic cells and regulatory T cells after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in patients with refractory cytopenia.
- To compare the results of chimerism obtained with standard short tandem nucleotide polymorphism PCR (sensitivity 1%) with those obtained with single nucleotide polymorphisms PCR (sensitivity 0.1- 0.01%).
Secondary
- To evaluate the relationship between mixed chimerism and hematological engraftment, overall survival, and event-free survival.
- To study the impact of mixed chimerism in plasmacytoid dendritic and regulatory T cells on the incidence of acute and chronic graft-versus-host-disease.
OUTLINE: This is a multicenter study.
Peripheral blood is collected from patients and donors prior to hematopoietic stem cell transplantation (HSCT). Patients also undergo blood sample collection on days 30, 60, 100, and 180 after transplantation. Peripheral blood cells are enriched and separated into lineage-specific subpopulations (i.e., CD3, CD14, CD15, CD19, and CD56) which are then divided equally for either DNA isolation via PCR or for flow cytometry. DNA concentrations in pre-HSCT donor and patient samples and in post-HSCT subpopulation samples are determined using quantitative real-time PCR. Samples are also analyzed for quantification of chimerism and detection of genetic markers via short tandem repeats- and sequence nucleotide polymorphism-based chimerism analyses.
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosed with refractory cytopenia
- Hypocellular bone marrow and normal karyotype
Underwent stem cell transplantation (SCT) from an HLA identical (8/8) sibling, an HLA identical (10/10) relative, or an HLA identical or single allelic disparate unrelated donor
- Received a preparative regimen including either thiotepa or fludarabine phosphate
- Concurrently enrolled on EWOG-MDS-2006
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations| Austria | |
| St. Anna Children's Hospital | Recruiting |
| Vienna, Austria, A-1090 | |
| Contact: Contact Person 43-1-401-700 trebo@ccri.univie.ac.at | |
| Belgium | |
| Ghent University | Recruiting |
| Ghent, Belgium, B-9000 | |
| Contact: Contact Person 32-9240-3875 barbara.demoerloose@ugent.be | |
| Czech Republic | |
| University Hospital Motol | Recruiting |
| Prague, Czech Republic, 150 06 | |
| Contact: Contact Person 42-022-443-6401 jan.stary@lfmotol.cuni.cz | |
| Denmark | |
| Aarhus Universitetshospital - Aarhus Sygehus | Recruiting |
| Aarhus, Denmark, DK-8000 | |
| Contact: Contact Person 45-8949-6841 hasle@dadlnet.dk | |
| Germany | |
| European Working Group of MDS in Childhood | Recruiting |
| Freiburg, Germany, 79106 | |
| Contact: Contact 49-761-270-4617 Peter.Bader@kgu.de | |
| Universitaetskinderklinik - Universitaetsklinikum Freiburg | Recruiting |
| Freiburg, Germany, D-79106 | |
| Contact: Contact Person 49-761-270-4506 ewog-mds@uniklini-freiburg.de | |
| Italy | |
| IRCCS "Casa Sollievo della Sofferenza" | Recruiting |
| South Giovanni Rotondo, Italy, 71013 | |
| Contact: Contact person 39-038-250-1251 m.zecca@smatteo.pv.it | |
| Netherlands | |
| Erasmus MC - Sophia Children's Hospital | Recruiting |
| Rotterdam, Netherlands, 3015 GJ | |
| Contact: Contact Person 31-104-636-691 m.vandenheuvel@erasmusmc.nl | |
| Poland | |
| Akademia Medyczna im. Piastow Slaskich | Recruiting |
| Wroclaw, Poland, 50-367 | |
| Contact: Contact Person 48-71-328-2040 wojcikd@pedhemat.am.wroc.pl | |
| Switzerland | |
| University Children's Hospital | Recruiting |
| Zurich, Switzerland, CH-8032 | |
| Contact: Contact Person 41-44-266-7723 eva.bergstraesser@kispi.unizh.ch | |
| Principal Investigator: | Peter Bader, MD | European Working Group of MDS in Childhood |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00898118 History of Changes |
| Other Study ID Numbers: | CDR0000587523, EWOG-MDS-SCT RC RIC-06, EU-20808 |
| Study First Received: | May 9, 2009 |
| Last Updated: | May 9, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
refractory cytopenia with multilineage dysplasia childhood myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes |
Additional relevant MeSH terms:
|
Leukemia Myelodysplastic Syndromes Preleukemia Neoplasms by Histologic Type |
Neoplasms Bone Marrow Diseases Hematologic Diseases Precancerous Conditions |
ClinicalTrials.gov processed this record on May 23, 2013